Problem poser - How to interpret divergent prognostic evidence of simultaneously measured tumor markers?

Computational and Mathematical Methods in Medicine

Volumn 8, Issue 1, 2007, Pages 71-75

  Klinge, U ^a,b   Dahl, E ^b   Mertens, P R ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKERS;

TUMORS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER; Y BOX BINDING PROTEIN 1;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION COEFFICIENT; GENE EXPRESSION; HUMAN; PREDICTION; PROGNOSIS; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH;

EID: 34547113529     PISSN: 1748670X     EISSN: 17486718     Source Type: Journal    
DOI: 10.1080/17486700701297758     Document Type: Article

References (8)

1. Jeong, H., Tombor, B., Albert, R., Oltvai, Z.N. and Barabasi, A.L. (2000) The large-scale organization of metabolic networks. Nature, 407:6804, pp. 651-654.
2. Albert, R., Jeong, H. and Barabasi, A.L. (2000) Error and attack tolerance of complex networks. Nature, 406:6794, pp. 378-382.
3. Arpino, G., Weiss, H. and Lee, A.V. (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. Journal of the National Cancer Institute, 97:17, pp. 1254-1261.
4. Kute, T.E., Russell, G.B. and Zbieranski, N. (2004) Prognostic markers in node-negative breast cancer: A prospective study. Cytometry Part B, Clinical Cytometry, 59:1, pp. 24-31.
5. Osanai, T., Takagi, Y. and Toriya, Y. (2005) Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Japanese Journal of Clinical Oncology, 35:3, pp. 121-125.
6. Gurkan, A., Erdogan, G. and Erdogan, O. (2004) Expression of c-erbB-2 and p53 in breast carcinoma patients: Comparison with traditional prognostic factors and survival. The Journal of International Medical Research, 32:5, pp. 455-464.
7. Pellikainen, J.M., Ropponen, K.M., Kataja, V.V., Kellokoski, J.K., Eskelinen, M.J. and Kosma, V.M. (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clinical Cancer Research, 10:22, pp. 7621-7628.
8. Janz, M., Harbeck, N. and Dettmar, P. (2002) Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. International Journal of Cancer, 97:3, pp. 278-282.